N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide 分子结构式
HCID67469117

N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide

N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-[6-(4-methylpiperazin-1-yl)-3-pyridinyl]-1-propan-2-ylindole-4-carboxamide

C31H38N6O2526.7 g/mol

IDENTITY

结构与身份

标准SMILES
Cc1cc(C)c(CNC(=O)c2cc(-c3ccc(N4CCN(C)CC4)nc3)cc3c2c(C)cn3C(C)C)c(=O)[nH]1
InChIKey
HRDQQHUKUIKFHT-UHFFFAOYSA-N
分子式
C31H38N6O2
平均分子量
526.7 g/mol
单同位素质量
526.30562448

COMPUTED

结构计算性质

已同步
XLogP
3.8
极性表面积
82.5 Ų
氢键供体
2
氢键受体
5
可旋转键
6
重原子
39
形式电荷
0
复杂度
984

ALIASES

名称与别名

共 36 条
GSK5031346572-63-1N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamideGSK-503GSK 503MFCD28405142N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1-propan-2-ylindole-4-carboxamideGSK-503?EZH2 inhibitororb1226484orb1307466SCHEMBL2595868CHEMBL3909511SCHEMBL29351554EX-A613GSK503?CHEBI:231340HRDQQHUKUIKFHT-UHFFFAOYSA-NGLXC-06400GSK2635503Cs7804

REACTIONS

参与反应

6
HRID 42402 反应方程式

uspto-grants-2013_09 · 10.6084/m9.figshare.5104873.v1 · US08536179B2

查看
HRID 62300 反应方程式

uspto-grants-2016_09 · 10.6084/m9.figshare.5104873.v1 · US09446041B2

查看
HRID 516660 反应方程式

uspto-grants-2015_08 · 10.6084/m9.figshare.5104873.v1 · US09114141B2

查看
HRID 593780 反应方程式

uspto-grants-2016_01 · 10.6084/m9.figshare.5104873.v1 · US09242962B2

查看
HRID 873353 反应方程式

uspto-grants-2015_03 · 10.6084/m9.figshare.5104873.v1 · US08975291B2

查看
HRID 1476935 反应方程式

uspto-grants-2016_08 · 10.6084/m9.figshare.5104873.v1 · US09402836B2

查看